Yitian Chen

1. Managed laboratory reagent procurement and reimbursement processes.

2. Investigated the role of HMGB1 in mechanisms of drug resistance in hepatocellular carcinoma.

1. Mainly using animal model to elucidate the precise mechanisms regulating intermediate AT2 cells biology and accumulation in lung fibrosis (IPF, AE-IPF).

2. Investigating the therapeutic potential of intermediate AT2 cells, which is the stem-like cells in lung regeneration.

3. Leverage spatial transcriptomes, mIHC (TSA) experiment to generate a spatial niche involved the crosstalk between AT2 and immune microenvironment.

4. Performed in vivo lineage tracing of targeted fibroblast and co-cultured it with AT2 to support proposal in vitro and vivo.

1. Applied IMC to help Chongqing Daping Hospital to investigate the reason of drug resistance in colon cancer "Spatiotemporal determinants of response to neoadjuvant radiotherapy and immunochemotherapy in locally advanced mismatch repair proficient rectal cancer (TRIUNITE-01):a phase 2 trial".

2. Tested lung cancer FFPE slides using different mIHC methods, like MACSima platform (cooperated with University of Hong Kong) and Akoya PhenoImager Fusion.

3. Assist fund declaration: FDCT-MOST (with Shanghai Jiaotong University), NSFC-FDCT (with Hunan University) and FDCT.

4. Laboratory instruments and reagents management.

Worked as a Research Assistant in the Faculty of Health Sciences.

Conducted medical experiments in biological immunology and microbiology departments, clinical laboratory and blood transfusion department.

Completion of graduation thesis with the supervision of Lily Gu. Support in clinical experiments and results analysis.